KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Castle Biosciences (CSTL) Other Operating Expenses (2019 - 2026)

Castle Biosciences' Other Operating Expenses history spans 7 years, with the latest figure at $20.6 million for Q4 2025.

  • On a quarterly basis, Other Operating Expenses changed 0.33% to $20.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $105.9 million, a 48.46% increase, with the full-year FY2025 number at $105.9 million, up 48.46% from a year prior.
  • Other Operating Expenses hit $20.6 million in Q4 2025 for Castle Biosciences, down from $21.0 million in the prior quarter.
  • Over the last five years, Other Operating Expenses for CSTL hit a ceiling of $44.7 million in Q1 2025 and a floor of -$10.6 million in Q2 2022.
  • Historically, Other Operating Expenses has averaged $14.1 million across 5 years, with a median of $13.6 million in 2023.
  • Biggest five-year swings in Other Operating Expenses: surged 1397.35% in 2021 and later crashed 368.53% in 2022.
  • Tracing CSTL's Other Operating Expenses over 5 years: stood at $5.6 million in 2021, then skyrocketed by 104.01% to $11.4 million in 2022, then grew by 28.5% to $14.7 million in 2023, then skyrocketed by 39.67% to $20.5 million in 2024, then rose by 0.33% to $20.6 million in 2025.
  • Business Quant data shows Other Operating Expenses for CSTL at $20.6 million in Q4 2025, $21.0 million in Q3 2025, and $19.6 million in Q2 2025.